2016

Is Vitamin D Supplementation Effective at Reducing Idiopathic Musculoskeletal (MSS) Pain?

Darra O. Markland
Philadelphia College of Osteopathic Medicine, darrama@pcom.edu

Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews

Part of the Musculoskeletal Diseases Commons

Recommended Citation
http://digitalcommons.pcom.edu/pa_systematic_reviews/296

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Is Vitamin D Supplementation Effective at Reducing Idiopathic Musculoskeletal (MSS) Pain?

Darra O. Markland, PA-S

A SELECTIVE EVIDENCE BASED MEDICINE REVIEW

In Partial Fulfillment of the Requirements For

The Degree of Master of Science

In

Health Sciences – Physician Assistant

Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

December 18, 2015
Abstract

Objective: The objective of this selective EBM review is to determine “Is Vitamin D supplementation effective at reducing idiopathic musculoskeletal (MSS) pain?”

Study Design: Review of primary studies published between the years 2012-2014.

Data Sources: One double blind randomized controlled trial (RCT), one semi-crossover RCT, and one before and after observational study. These were found using Cochrane Review and PubMed databases.

Outcomes Measured: Clinical outcomes were measured in these studies utilizing the Visual Analogue Scale for Pain, the 5-point Likert Pain Scale, the Standard Nordic Questionnaires and numerical grading of pain level, and number of pain sites before and after Vitamin D₃ supplementation.

Results: In a RCT by Knutsen et. al (2014), pain scores were improved in the experimental group receiving supplementation with Vitamin D₃ as compared to placebo, but results were not significant. The double-blind, semi-crossover RCT by Schreuder et. al (2012) found significant improvement in nonspecific MSS pain after 6 weeks of Vitamin D₃ supplementation and mixed results after 12 weeks of supplementation. The before and after observational study performed by Le Goaziou et. al (2014) also found significantly decreased pain sensation in participants after Vitamin D₃ supplementation as compared to baseline.

Conclusions: There is conflicting data in regard to the relationship between Vitamin D stores and MSS pain. To determine whether or not Vitamin D₃ supplementation significantly improves idiopathic MSS pain, there needs to be more double-blind randomized controlled trials performed for analysis.

Keywords: Vitamin D, musculoskeletal pain
INTRODUCTION

Pain is the most common complaint that health care providers treat. Chronic pain is characterized as painful symptoms lasting for at least a three month duration. Pain of musculoskeletal origin can be the result of underlying disease processes such as inflammatory or autoimmune conditions, infections, neoplasms, renal deficiency, hyperlipidemia, advanced age, pharmacotherapeutic reactions, or idiopathic in origin. Whether there is a link between Vitamin D deficiency and idiopathic musculoskeletal pain is controversial. This paper evaluates three clinical trials that considered the efficacy of Vitamin D3 supplementation for improving nonspecific, idiopathic musculoskeletal pain.

More than 20% of outpatient visits are based on musculoskeletal complaints (both chronic and acute), comprising more than 315 million outpatient visits annually. The average healthcare expenditure on chronic pain management in the US is $125 billion, with low back pain alone costing around $86 billion. Vitamin D deficiency, defined as 25(OH)D serum levels less than 20 ng/mL, affects 29% of post-menopausal women and 25% of men over the age of 65 years old in the U.S. Recent interest in the potential sequelae of Vitamin D deficiency, including musculoskeletal pain, has prompted over-the-counter Vitamin D supplementation purchases to rise nearly 10-fold throughout the early 2000’s.

It has been proposed that chronic pain is influenced by three key factors: an incurable disease, unresolved neural factors from a previous disease, or psychological conditions such as anxiety or depression. However, these explanations do not account for the etiology or pathophysiology of idiopathic musculoskeletal pain. It is known that the sensation of pain itself is due to neuropathic processes originating in the body’s nociceptive sensory stimuli. These communicate via the thalamus, brainstem and somatosensory cortex to evoke an emotional
response regulated by both the limbic system and neurotransmitters such as serotonin and norepinephrine. Vitamin D might indirectly have an effect on this pain perception since it enhances bone mineral composition by increasing the body’s absorption of calcium and phosphorus. Theoretically, this could have a profound impact on musculoskeletal symptoms as hypocalcemia predisposes individuals to rickets and osteomalacia while hypophosphatemia can induce muscle weakness, bone pain and decreased bone integrity. In support of this theory, a higher frequency of musculoskeletal pain has been reported among Vitamin D deficient individuals indigenous to areas with low sunlight exposure. Furthermore, Vitamin D receptors are found in most cells and tissues throughout the body, including muscle cells and immune cells, reinforcing its potential influence on idiopathic musculoskeletal pain.

Since idiopathic musculoskeletal pain has unknown causation, the current standard approach to treatment is multidisciplinary and palliative. This includes NSAIDs and acetaminophen for mild to moderate symptom relief along with heat and cryotherapy. Modalities such as physical therapy and acupuncture can be beneficial as well. Long-acting opioids, such as morphine and oxycodone, are implemented with caution for debilitating pain unresponsive to aforementioned approaches. Because chronic musculoskeletal pain can be a psychosomatic manifestation of an underlying psychiatric disorder, a trial of cognitive behavioral therapy or tricyclic antidepressants can sometimes reveal an undiagnosed mood disorder and provide relief. The pathophysiology of Vitamin D suggests a potentially promising and affordable treatment alternative for joint and muscle pain with a favorable risk-benefit ratio.

**OBJECTIVE**

The objective of this selective EBM review is to determine “Is Vitamin D supplementation effective at reducing idiopathic musculoskeletal (MSS) pain?”
METHODS

This investigation looks at two double-blind randomized controlled trials, including one semi-crossover study, and one observational before and after study. Each study included both male and female Vitamin D deficient participants with similar demographic parameters amongst experimental and placebo groups in the controlled trials. \(^7,8,9\) Knutsen et. al utilized one experimental group combined of participants receiving 10µg or 25µg of Vitamin D\(_3\) as compared to a control group receiving a visibly matched placebo. \(^7\) The semi-crossover controlled trial by Schreuder et. al gave one experimental group a single 150,000 IU dose at baseline and again at 6 weeks, the second experimental group a 150,000 IU dose of Vitamin D\(_3\) at baseline followed by a visually matched placebo at 6 weeks, and the third group received a placebo at baseline followed by a single 150,000 IU dose of Vitamin D\(_3\) at 6 weeks. \(^8\) Outcomes at 6 weeks and 12 weeks were measured. \(^8\) Participants in the before and after observational study received between 400,000 to 600,000 IU of Vitamin D\(_3\) dependent upon individual baseline serum Vitamin D levels. \(^9\) All studies examined patient oriented outcomes by evaluating changes in MSS pain from baseline in response to improved Vitamin D deficiency. \(^7,8,9\)

This systematic review included searches in the Cochrane Review and PubMed databases. The two randomized controlled trials were published in peer reviewed English journals between the years of 2012 to 2014. Le Goaziou et. al published their work in French the 2014 Edition of the European Journal of General Practice, which was then translated into English. Key words utilized to find these articles were “Vitamin D” and “musculoskeletal pain.” Each study utilized similar inclusion and exclusion criteria with more stringent exclusion parameters in the two controlled trials as demonstrated by Table 1. The inclusion criteria included adults aged 18 to 60 years-old with chronic MSS pain of unknown origin who had been
diagnosed with Vitamin D deficiency. This review attempted to exclude studies with participants who had comorbidities that could interfere with Vitamin D metabolism. The inclusion and exclusion criteria for each study is outlined below (see Table 1).

Table 1: Demographics & Characteristics of Included Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th># Pts</th>
<th>Age (yrs)</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
<th>W/D</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schreuder (2012)</td>
<td>Semi-crossover randomized controlled trial</td>
<td>84</td>
<td>18-60 years old</td>
<td>≥ 1 parent born in a non-Western country. Vitamin D &lt;50 nmol/L. &gt; 3 nonspecific MSS pain episodes of &gt;1 month duration in 2 years, or ongoing for 3 months, without obvious cause</td>
<td>Pregnancy, Rickets, Sarcoidosis or Tuberculosis. Use of statins, cyclosporines or oral steroids. Use of Vitamin D in last 4 mo’s. Ca &gt; 2.55 mmol/L. Cr &gt; 150 mmol/L ESR &gt; 30 mm/h.</td>
<td>5</td>
<td>1 dose of Vitamin D₃ 150,000 IU verses placebo. Evaluated at 6 wks and again at 12 wks</td>
</tr>
<tr>
<td>Knutsen (2014)</td>
<td>Double-blind randomized controlled trial</td>
<td>251</td>
<td>18-50 years old</td>
<td>Assumed healthy population experiencing MSS pain. Vitamin D &lt;50 nmol/L. Born in or children of parents born in the Middle East, Africa or South Asia.</td>
<td>Same as above except no exclusion of statins or cyclosporines and no lab testing parameters. Plus exclusion of breastfeeding, CA, renal disease, osteoporosis, recent fracture and the use of pain killers, thiazides, epileptics or HRT</td>
<td>36</td>
<td>Vitamin D₃, 10 µg or 25 µg PO qd x 16 weeks</td>
</tr>
<tr>
<td>Le Goaziou (2014)</td>
<td>Before and after observational study</td>
<td>69</td>
<td>18-50 years old</td>
<td>Diffuse MSS pain. Vitamin D &lt;50 nmol/L.</td>
<td>Identified causation of MSS pain</td>
<td>20</td>
<td>1 dose of 400-600,000 IU Vitamin D₃. Examined 45-60 days later.</td>
</tr>
</tbody>
</table>
Schreuder et al outlined parameters to specify chronicity of pain, classified as at least 3 episodes of 1 month duration of pain for 2 years or continuous pain for 3 months, whereas Knutsen et al and Le Goaziou et al selected participants who sought consultation from their general practitioner for MSS pain.\textsuperscript{7,8,9} Exclusion criteria included in both randomized controlled trials were pregnancy, renal disease, tuberculosis, sarcoidosis or osteoporosis, and use of Vitamin D supplements or medications that interfere with Vitamin D metabolism. Exclusion criteria specific to Schreuder et al included signs of rickets, ESR > 30 mm/h, serum calcium > 2.55 mmol/L, and serum creatinine > 150 mmol/L.\textsuperscript{8} Exclusion criteria specific to the study by Knutsen et al included use of strong pain medication, breastfeeding or a recent fracture.\textsuperscript{7} Le Goaziou et al did not disclose exclusion criteria for the observational study, however phototype, body mass index, use of body-covering clothes, diet, sun exposure, pain, fatigue, impact of pain on quality of life and health insurance coverage were considered and matched to the best capacity when selecting study participants.\textsuperscript{9}

Statistical analysis in all three studies utilized p values to determine the significance of mean changes in pain from baseline. Only Schreuder et al reported dichotomous data, which allowed for calculation of the control event rate (CER), experimental event rate (EER), relative benefit increase (RBI), and absolute benefit increase (ABI). The numbers needed to treat (NNT) was then determined from the ABI, while numbers needed to harm (NNH) was not applicable due to absence of significant adverse participant outcomes.\textsuperscript{8} This study utilized the Pearson $X^2$ test to determine an association between VAS reports and Likert Scale scores, which allowed for imputation of missing Likert scales for four participants who were lost to follow up.\textsuperscript{8} Knutsen et al reported the odds ratio (OR) and confidence interval (CI) of the study’s results and utilized the Generalized Estimating Equation Poisson Regression Model to adjust outcome variables and
account for the likelihood that reported pain levels were influenced by participants’ number of pain sites. Le Goaziou et. al utilized a Chi-Square Test for baseline data to determine post-intervention comparison. The evolution of mean pain scores was then determined with mixed model analysis and adjusted for BMI, age and gender.

OUTCOMES MEASURED

All three studies examined the efficacy of Vitamin D₃ supplementation to decrease MSS pain levels in individuals with Vitamin D deficiency. Knutsen et. al examined its effects on pain parameters as demonstrated by changes in reported MSS pain, utilizing the Standard Nordic Questionnaire, after 16 weeks of supplementation. Schreuder et. al had participants record pain results on the following 5-point Likert Scale: Much Less Pain, Less Pain, Equal Pain, More Pain, or Much More Pain. This was measured at 6 weeks and again at 12 weeks into the study. The location and intensity of pain was also measured with VAS questionnaires, scaled from 0-100 (0 translating as “no pain” and 100 translating as “worst imaginable pain), with consideration of four key pain sites (shoulder, low back, arms and legs and joints). Le Goaziou et. al measured a mean pain evaluation score with a questionnaire that specified the location of pain, duration of pain, intensity of pain, and the use of analgesics.

RESULTS

All three of these studies yielded different results about the effects of Vitamin D₃ supplementation on MSS pain. The Likert scale pain scores collected by Schreuder et. al yielded statistically significant decreases in pain levels, with 34.9% improvement in the Vitamin D₃ group of 44 participants compared to 19.5% improvement in the placebo group of 40 participants (P=0.04), yielding 7 numbers needed to treat (see Table 2). These values were calculated with imputation for missing data (however, calculations without imputation also yielded statistically
significant improvement). At 12 weeks, the only statistically significant difference in pain relief on Likert Scales was seen between the group of 24 participants that received Vitamin D₃ for both interventions, with a 61.9% improvement rate, verses the arm comprised of 33 participants that received placebo for the first 6 weeks then Vitamin D₃ for the second 6 weeks, with a 12.6% improvement rate (P=0.005). This difference yielded 3 numbers needed to treat (see Table 2). The difference in pain scales between Vitamin D-Vitamin D vs. Vitamin D-Placebo groups as well as the Vitamin D-Placebo and Placebo-Vitamin D groups in this semi-crossover clinical trial yielded no statistically significant results, with p-values > 0.05 in both instances. This data is based on a total of 79 participants during the first 6 week analysis (after losing 5 participants to follow up) and 69 participants in the second analysis at 12 weeks, resulting in an 18% total loss to follow-up in this study.

Table 2: Calculations for treatment from Schreuder et. al

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Treatment Interval</th>
<th>CER</th>
<th>EER</th>
<th>RBI</th>
<th>ABI</th>
<th>NNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D vs. Placebo</td>
<td>6 weeks</td>
<td>19.5%</td>
<td>34.9%</td>
<td>78.97%</td>
<td>15.4%</td>
<td>7</td>
</tr>
<tr>
<td>Vitamin D-Vitamin D vs. Placebo-Vitamin D</td>
<td>12 weeks</td>
<td>12.6%</td>
<td>61.9%</td>
<td>391%</td>
<td>49.3%</td>
<td>3</td>
</tr>
</tbody>
</table>

The observational study by Le Goaziou et. al also found a statistically significant difference between baseline and post-intervention results. Mean pain values at baseline were 5.1 and decreased to 2.8 when measured at follow up after their single dose of Vitamin D₃ intervention (P<0.001). (See Figure 1) The scaling for reported data was not specified. There were initially 69 participants in this study with a 29% loss to follow-up, resulting in a total of 49 participants.
The RCT by Knutsen et. al did not demonstrate statistically significant changes in pain level with Vitamin D₃ supplementation. The Vitamin D group reported a 20% decrease in pain, similar to the control group that reported an 18% decrease in pain (P=0.82). The confidence interval (CI) of these reported results was large (0.34-3.96) and the odds ratio (OR) was 1.15 once values were adjusted for age, gender and baseline Vitamin D₃ level, indicating that the intervention was not effective (See Figure 2). The study began with 251 eligible participants, and concluded with 215 participants, resulting in an approximate 15% loss to follow-up. Out of those participants, 180 individuals returned their Vitamin D₃ tablet boxes as requested for compliance analysis. 80% of the cohort had consumed 80% of the allotted tablets while 69% had consumed 90% of the tablets.
All three studies reported minimal to no adverse effects that were unrelated to the intervention. Knutsen et. al reported that 21 of their participants experienced new onset of symptoms. However, these were distributed equally amongst placebo and control groups and not attributable experimental supplementation. Vitamin D₃ is a naturally metabolized substance and all participants were deficient in the nutrient. It takes chronic ingestion of more than 40,000-100,000 IU per day to reach Vitamin D₃ toxicity, so this was not of concern.

**DISCUSSION**

Vitamin D₃ has received public attention in recent years for its potential link to chronic conditions such as unexplained depression, MSS pain, cancers, cardiovascular disease and metabolic disorders. The potential efficacy of this nutrient is valuable because patients who seek care for idiopathic MSS pain have few safe and affordable long-term treatment options. Palliative modalities such as physical therapy, massage and acupuncture relief often do not qualify for insurance coverage. Chronic NSAID use can result in gastric bleeding or ulceration, while chronic ASA use can induce hepatotoxicity. Opioids impose risk of dependency and have potent ADR’s that interfere with activities of daily living, most notably chronic constipation, cognitive impairment and dependence. Vitamin D₃ is a safe and affordable over-the-counter alternative that is naturally metabolized by the hepatic and renal systems without proven adverse effects when utilized at the recommended daily doses.

Although two of the included studies demonstrated some improvement in MSS pain with Vitamin D₃ supplementation, limitations in these studies challenge the efficacy of reported results. One key outlier was the inconsistency in regulation of pain relieving medications among participants. Schreuder et. al attempted to standardize this variable by allowing participants to use pain relieving medications and record their usage, which was similar across groups, and
Knutsen et al. measured pain medication uses as an outcome variable. However, analgesic effects on pain perception could have a profound impact on reported pain scales. Furthermore, although researchers attempted to match baseline pain levels amongst participants, individualized pain thresholds make it difficult to draw objective conclusions from study results.

There were other limitations that may have affected the outcome of these studies such as the relatively short duration of each trial. For instance, some participants in the study by Knutsen et al. did not surpass the level of Vitamin D deficiency by trial’s conclusion. This suggests that a longer duration of supplementation might potentially lead to more pronounced and significant improvements. The RCT by Knutsen et al. also relied on participants to comply with daily doses of Vitamin D3 supplements, which resulted in altered outcomes from a degree of noncompliance as reported by the study (see Results section). Furthermore, the participant selection criteria for these studies did not account for all of conditions that could affect chronic pain as well as the metabolism of Vitamin D. Of particular concern, these trials did not disclose if screening for psychological conditions was performed. Since mental health conditions can manifest psychosomatically as pain, participants in these studies may have had underlying conditions influencing their pain perception that cannot be treated by vitamin supplementation.

Additionally, only Schreuder et al. excluded participants who had excess serum concentration of minerals that could influence Vitamin D metabolism and MSS pain. Meanwhile, Knutsen et al. simply excluded a handful of the many conditions that influence these factors and Le Goaziou et al. neglected to outline specific exclusion criteria. Without stringent inclusion and exclusion criteria, the efficacy of interventions in these studies is questionable.

Validity was an issue in all three studies. The study by Le Goaziou et al. had the most profound improvement in pain, however it was the least valid study. This research could not
establish a causal effect from the intervention due to the fact that it was an observational study that did not keep participants or researchers blind to the intervention.\textsuperscript{9} Furthermore, the study had loss to follow-up rates exceeding 20%.\textsuperscript{9} Knutsen et. al did implement a more reliable randomized controlled trial to measure data, however researchers combined the two experimental arms receiving 10µg and 25µg of Vitamin D\textsubscript{3} daily and compared these groups as a whole to the control.\textsuperscript{7} It is questionable why the researchers chose this approach, and the grouping of two differently dosed interventions decreases the validity of the results.\textsuperscript{7} While Schreuder et. al did find improvement in pain reports via the Likert Scale, there was conflicting data amongst the three study arms.\textsuperscript{8} The reason for this is unclear, but the inconsistency decreases the likelihood of reproducible results.

**CONCLUSION**

Despite its potential appeal, existing data is inconclusive in determining whether or not Vitamin D\textsubscript{3} is an effective means of alleviating idiopathic musculoskeletal pain. Although these studies attempted to account for a number of potential outliers, it is difficult to guarantee validity in studies that rely on patient oriented outcomes such as pain scale due to its subjectivity. In order to control for these factors, future studies designed as double-blind randomized controlled trials need to be taken underway. Future studies should be longer in duration, should have extensive screening protocols for pain-inducing comorbidities, and should implement ongoing extraneous analgesic control. Until more reliable studies are complete, it cannot be confirmed whether supplementation with Vitamin D\textsubscript{3} can improve idiopathic MSS pain in individuals who are Vitamin D deficient.
Works Consulted


